and 44 years of age found it quite difficult to conceive naturally or even via the use of intrauterine insemination. ART and IVF treatments now play an important role in the field of infertility treatment and have made a significant contribution to the increased number of newborns. The number of infertile patients with advanced maternal age (≥40 years) has seen a recent increase. Even with the increased use of ART treatment, however, the pregnancy rates are not yet satisfactory among patients who are more than 40 years of age. The miscarriage rate, unfortunately, has increased due to these increases in the advanced maternal age. 4 Indeed, there were 6658 cycles planned for oocyte pickup (OPU) for ART treatment at Sugiyama Clinic between January and December in 2016, and 48.1% (3201 cycles) of them were for patients who were more than 40 years of age. This recent trend is not exclusive to our clinic, but in fact is becoming common in Japan.
The clinicians working at the Department of Reproductive
Medicine and in clinics that specialize in infertility treatment encounter many patients among these age-groups every day. Even though the success rate of IVF treatment for these patients is relatively low even when using ART treatment, these may be the only viable options for infertile patients with advanced maternal age. When devising strategies to overcome the poor success rate, two main questions often must be answered: one is that whether ovarian stimulation is needed or not, and the other is whether intracytoplasmic sperm injection (ICSI) be better than conventional insemination as an insemination method for patients who may have only one mature oocyte? In this article, we expanded on and discuss these two main points. In addition, our strategy for the patients showing unsynchronized follicular growth is also introduced.
| IS OVARIAN S TIMUL ATI ON NEEDED FOR THE PATIENTS WITH ADVAN CED MATERNAL AG E?
Between 2012 and 2016, a total of 3545 cycles were recruited for analysis. The patients recruited in these treatment cycles satisfied the following two conditions: They were more than 40 years of age at the time of OPU and they had used OPU <2 times. Moreover, all patients had received fresh embryo transfers, and patients receiving cryopreserved embryos were excluded, because these embryos did not always reflect the maternal age (cryopreservation of embryos could make the difference of the patients' age between the cryopreservation day and embryo transfer day). All cycles were divided into one of two groups: the stimulation group and the minimal stimulation group. There were 1666 cycles in the stimulation group, and this group received ovarian stimulation that included either the gonadotropin-releasing hormone (GnRH)-agonist long patients in the stimulation group, 7.1% (n = 118) of total cycles resulted in no usable oocytes for the following reasons: cancelation of OPU for just after ovulation (n = 48), no oocyte to retrieve (n = 26), or retrieval of a degenerated oocyte (n = 44). By contrast, the percentage of patients who could obtain no usable oocytes in the minimal stimulation group was 49.0% (n = 920), which was significantly higher than that in the stimulation group (P < 0.01). The reasons were the same: n = 580, n = 142, and n = 198, respectively. In the stimulation group, the OPU cancelation rate was 2.8%, which was significantly lower than that in the minimal stimulation group (30.9%, P < 0.01). In the stimulation group, patients received some agents to prevent ovulation such as GnRH-agonist, GnRH-antagonist, or CC, The average number of retrieved oocytes in the stimulation group was 4.2 ± 1.8, which was significantly higher than that in the minimal stimulation group (1.2 ± 0.3, P < 0.01). In the stimulation group, 1285
cycles of fresh embryo transfers were performed, and 164 patients achieved pregnancy for a clinical pregnancy rate per OPU of 9.8%.
On the other hand, in the minimal stimulation group, at 543 cycles fresh ET was performed, and 59 pregnancies were achieved. The clinical pregnancy rate per OPU was 3.1%, which was significantly lower than for the stimulation group ( Figure 1 ; P < 0.01). It was considered that two reasons might cause this result. One was that a higher number of retrieved oocytes were collected in the stimulation group compared with that in the minimal stimulation group. The other was that the rate of unusable oocytes in the stimulation group was lower compared with that in the minimal stimulation group. The half of the cycles scheduled of oocyte retrieval in the minimal stimulation group
could not proceed to the further step to fertilize. As a consequence, ovarian stimulation for the patients with advanced maternal age in ART treatment resulted in the achievement of a higher pregnancy rate; therefore, ovarian stimulation is recommended for these types of patients who receive ART treatment.
The only nearly 10% of the patients in the stimulation group
could not obtain usable oocytes in spite of receiving ovarian stimu- 
| IS I C S I NEEDED FOR THE PATIENTS WITH ADVAN CED MATERNAL AG E WHO C AN OBTAIN ONLY ONE OO C Y TE?
Clinicians sometimes face a situation whereby patients have only one follicle on the day of maturation trigger with or without ovarian stimulation, particularly those with advanced maternal age. Within the time period and recruited cycles mentioned above, the number of cycles that showed only one follicle for oocyte retrieval in the stimulation and minimal stimulation groups was 338 and 1791, respectively. In the stimulation group, at 107 cycles embryo transfer was performed, and six pregnancies were achieved. The clinical pregnancy rate per OPU and ET was 1.9% and 17.8%, respectively.
By contrast, in the minimal stimulation group, 39 pregnancies by the 385 transfers were achieved for clinical pregnancy rates per OPU and ET of 2.3% and 10.1%, respectively (Table 3 ). There were no significant differences between the two groups. Based on these data, ovarian stimulation would not have increased the clinical pregnancy rate for patients who showed only one developed follicle in reaction to the ovarian stimulation.
When clinicians must choose an insemination procedure for the patients with only one oocyte, the option is either ICSI or conventional insemination. Based on Japanese ART data, the ICSI cycle is more involved than a conventional insemination cycle, and this difference has grown for each of the past 3 years. 4 This trend seems to be a worldwide phenomenon. In general, the fertilization rate of ICSI is thought to be similar to that of conventional insemination. 9, 10 However, many patients and clinicians fervently believe that ICSI might be superior to conventional insemination with regard to F I G U R E 1 This graph indicates the clinical pregnancy rates per oocyte pickup in the stimulation and minimal stimulation groups. The rate in the stimulation group was 9.8% and was significantly higher than that in the minimal stimulation group (3.1%, P < 0.01) fertilization, because ICSI directly injects spermatozoa to the oocyte. For this reason, it is not uncommon that ICSI is selected as the insemination procedure for the patients who have only one oocyte.
Recently, we reported that the insemination procedure (conventional insemination or ICSI) had no influence on the outcome of ART treatment, and collecting only one oocyte is not an indication for
ICSI.
11 Therefore, for the patients who could obtain only one oocyte,
we compared the clinical pregnancy rate by ICSI-derived embryo with that by conventional insemination-derived embryo to evaluate which was more productive. The clinical pregnancy rate per ET derived from conventional insemination was 12.6%, which was significantly higher than that derived from ICSI (5.2%, P < 0.05; Figure 2 ).
Based on our data, compared with conventional insemination, ICSI
did not improve the clinical pregnancy rate. oocytes. In order to achieve pregnancy, ART treatment can provide many oocytes with one OPU procedure, which could improve the chances of selecting the best embryo or blastocyst for embryo transfer. It is difficult, however, for DOR patients to obtain a plurality of oocytes in one OPU. On the other hand, clinicians sometimes observe unsynchronized follicular growth during ovarian stimulation. In those cases, the dominant follicle size is a crucial maturation trigger, and subsequently, inadequately developed follicles are removed as a target of OPU, despite their value to DOR patients.
| DOUB LE OO C Y TE PI CKUP FOR THE PATIENTS WITH DOR AND S HOWING UNSYN CHRONIZED FOLLICUL AR G ROW TH DURING ART TRE ATMENT
Previously during ART treatment, if a patient's serum progesterone (P4) concentration was elevated (≥1.5 ng/mL) on the day maturation was triggered, OPU was usually canceled. This was the policy because an elevation of P4 reduces the rate of implantation , 12, 13 which could affect oocyte quality. 14 In a recent effort to avoid fresh embryo transfer, we reported that P4 elevation (≥1.5 ng/mL) on the day of maturation trigger could not decrease the pregnancy rate. 15 In the present study, moreover, we found that P4 elevation affected neither oocyte recovery rate nor embryo development rate. 15 On the other hand, the effectiveness of randomly beginning a protocol of ovarian stimulation has been reported. 16, 17 This protocol indicated that the decision to begin ovarian stimulation should not be related to the menstrual cycle.
When patients with DOR and low AMH levels receive ovarian stimulation, clinicians sometimes struggle with unsynchronized follicular growth. In these cases, OPU is performed according to the dominant follicle, and a small one could be ignored, or immature oocytes could be retrieved from the dominant follicle; as a consequence, this procedure would not improve the ART outcome. Therefore, for patients with DOR, a small follicle could be quite important and valu- TA B L E 3 Clinical outcomes of the cycles showing only one follicle in the stimulation and minimal stimulation groups
The clinical pregnancy rate per ET derived from the conventional insemination was 12.6%, which was significantly higher than that derived from intracytoplasmic sperm injection (5.2%, P < 0.05) was analyzed for DOR patients ≥40 years of age who showed unsynchronized follicular growth, and the outcome of DOR was analyzed.
From April 2016 to October 2017, we recruited patients with low AMH level (<1.0 ng/mL) who were more than 40 years of age and had received ovarian stimulation using only CC or a combination of CC and recombinant follicle-stimulating hormone (r-FSH), and 13 patients met the qualifications. The average age of the patients was 41.6 years, and the mean AMH (ng/mL) and basal follicle-stimulating hormone (FSH) levels (IU/L) were 0.47 and 15.1, respectively. Ten of the 13 patients were administrated either CC or CC with r-FSH injection.
| A PROTO COL OF DOUB LE OPU AND THE OUTCOME OF THIS PRO CEDURE
The protocol for double OPU is shown in Figure 3 Table 4 . The first and second OPUs resulted in the retrieval of 1.3 and 1.2 oocytes, respectively, for a total of 2.5. The mean number of MII oocytes on the first and second OPU was 1.1 and 1.2, respectively, and MII rates on the first and second OPU were 62.5% and 100%, respectively. The mean number of fertilized oocytes on the first and second OPU was 1.1 and 0.9, respectively, and the percentage of morphologically goodquality (MGQ) embryos on the first and second OPU was 33.3%
and 25.0%, respectively. Embryos were defined as MGQ embryos when they had developed to at least 6-cell stage with <20% fragmentation. 18 This system of embryo assessment was based on the classification system described by Veeck. 19 All embryos were not tried to develop to the blastocyst stage due to their small number of retrieved and fertilized oocytes.
Twelve out of the 13 patients were able to obtain cryopre- or less in diameter were not punctured. On the day of OPU, ovarian stimulation with r-FSH injection was started to induce growth in the smaller follicles. When the follicles reached 17 mm in diameter, the maturation trigger was completed, and 36 h later, a second OPU was performed. The embryos derived from the first and second OPU were cryopreserved the smaller ones were then stimulated with gonadotropins for the second OPU. This double OPU might be an effective procedure among the DOR patients to increase the number of collected oocytes (/patient) from the first and second rounds of OPU. During the first and second rounds of OPU, the usable embryos for cryopreservation numbered 10 and 5, respectively, and as a consequence, 12 of the patients were able to obtain cryopreserved embryos. Of these 12 patients, four were unable to obtain cryopreserved embryos without a second round of OPU.
Progesterone elevation on the day of the maturation trigger neither decreased the pregnancy rate when a fresh embryo transfer was avoided, nor affected the embryo development rate.
Furthermore, a random start was reported for ovarian stimulation. 16, 17 This of OPU is discounted considerably, which makes it easier for patients to choose a double OPU. More experience is needed for the establishment of a universal double-OPU protocol, which will require the application of this protocol to more patients.
| CON CLUS IONS
In our country, the number of women with advanced maternal age who choose to become pregnant increases every year. This means effective strategies are needed as soon as possible. There is no F I G U R E 4 At the first oocyte pickup (OPU), 12 out of 13 patients received oocytes, and 11 out of 13 received oocytes at the second OPU. Four patients (Patients 6, 7, 10, and 13) were able to cryopreserve embryos derived from the second OPU. Among them, a pregnancy was confirmed for Patient 4. 〇: oocytes that could be cryopreserved; : retrieved oocytes on the first OPU; : retrieved oocytes on the second OPU doubt that the transfer of euploid embryos or blastocysts is the most effective strategy for these women to achieve pregnancy, but the preimplantation genetic testing for aneuploidy (PGTA) is not allowed in our country. Moreover, the number of retrieved oocytes or developed embryos among the patients with advanced maternal age would likely be insufficient for PGTA due to either poor ovarian response or diminished ovarian reserve. In this article, we reviewed and compared the protocols and strategies that are available to increase the number of developed embryos.
We hope that this review will be helpful for both patients and
clinicians.
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